Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Cash from Investing Activities (2023 - 2025)

Immunocore Holdings' Cash from Investing Activities history spans 3 years, with the latest figure at -$880000.0 for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 75.14% year-over-year to -$880000.0; the TTM value through Dec 2025 reached -$16.3 million, up 95.4%, while the annual FY2025 figure was -$16.3 million, 95.4% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$880000.0 at Immunocore Holdings, down from $5.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $9.7 million in Q1 2025 and bottomed at -$350.3 million in Q2 2024.
  • The 3-year median for Cash from Investing Activities is -$854000.0 (2024), against an average of -$31.4 million.
  • The largest annual shift saw Cash from Investing Activities plummeted 25013.33% in 2024 before it surged 2356.28% in 2025.
  • A 3-year view of Cash from Investing Activities shows it stood at -$817000.0 in 2023, then tumbled by 333.29% to -$3.5 million in 2024, then skyrocketed by 75.14% to -$880000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Cash from Investing Activities are -$880000.0 (Q4 2025), $5.3 million (Q3 2025), and -$30.4 million (Q2 2025).